Telomir raises $2.9M via ATM stock sale

Telomir Pharmaceuticals, Inc. completed an at-the-market equity offering on August 28, 2025, selling 1,550,000 shares of common stock in block trades to institutional investors at an average price of $1.87 per share.

Accepted by SEC EDGAR 09/04/2025 - 10:13 AM EDT

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. completed an at-the-market equity offering on August 28, 2025, selling 1,550,000 shares of common stock in block trades to institutional investors at an average price of $1.87 per share. This generated gross proceeds of approximately $2.9 million before fees and expenses. The sales were executed through Rodman & Renshaw using the StockBlock platform and did not include any warrants.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) disclose in this 8-K?

Telomir Pharmaceuticals reported that on August 28, 2025, it completed an at-the-market equity offering, selling 1,550,000 shares of common stock to institutional investors for gross proceeds of approximately $2.9 million.

How many Telomir (TELO) shares were sold and at what price?

The company sold 1,550,000 shares of its common stock at an average price of $1.87 per share in block sales to institutional investors.

How much cash did Telomir Pharmaceuticals (TELO) raise in this transaction?

Gross proceeds from the offering were approximately $2.9 million, before deducting fees and expenses associated with the transaction.

What type of offering did Telomir (TELO) use for this capital raise?

Telomir used its at-the-market equity offering facility to conduct block sales of common stock to institutional investors.

Were any warrants issued in Telomir’s August 28, 2025 offering?

No. The offering consisted solely of common stock; it did not include any warrants.

Who facilitated Telomir Pharmaceuticals’ block sales of stock?

The trades were facilitated through Rodman & Renshaw via the StockBlock platform, as part of the at-the-market equity offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida

001-41952

87-2606031

(State or Other Jurisdiction
of Incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On August 28, 2025, Telomir Pharmaceuticals, Inc., completed its sale of a total of 1,550,000 shares of its common stock, no par value, in block sales to institutional investors, at an average price of $1.87 per share (a premium to the prior day’s close), through its at-the-market equity offering facility (the “Offering”). Gross proceeds from the Offering totaled approximately $2.9 million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock platform. The Offering did not include any warrants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.

Dated: September 4, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR